Wangge G - Search Results

1

Phase IV non-inferiority trials and additional claims of benefit.

Bernabe RD, Wangge G, Knol MJ, Klungel OH, van Delden JJ, de Boer A, Hoes AW, Raaijmakers JA, van Thiel GJ. Bernabe RD, et al. Among authors: wangge g. BMC Med Res Methodol. 2013 May 30;13:70. doi: 10.1186/1471-2288-13-70. BMC Med Res Methodol. 2013. PMID: 23721202 Free PMC article. Clinical Trial.

2

Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.

Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Wangge G, et al. PLoS One. 2010 Oct 27;5(10):e13550. doi: 10.1371/journal.pone.0013550. PLoS One. 2010. PMID: 21048948 Free PMC article. Review.

3

Should non-inferiority drug trials be banned altogether?

Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Wangge G, et al. Drug Discov Today. 2013 Jun;18(11-12):601-4. doi: 10.1016/j.drudis.2013.01.003. Epub 2013 Jan 14. Drug Discov Today. 2013. PMID: 23328201

4

Regulatory scientific advice on non-inferiority drug trials.

Wangge G, Putzeist M, Knol MJ, Klungel OH, Gispen-De Wied CC, de Boer A, Hoes AW, Leufkens HG, Mantel-Teeuwisse AK. Wangge G, et al. PLoS One. 2013 Sep 5;8(9):e74818. doi: 10.1371/journal.pone.0074818. eCollection 2013. PLoS One. 2013. PMID: 24040346 Free PMC article.

5

Interpretation and inference in noninferiority randomized controlled trials in drug research.

Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ. Wangge G, et al. Clin Pharmacol Ther. 2010 Sep;88(3):420-3. doi: 10.1038/clpt.2010.134. Epub 2010 Jul 28. Clin Pharmacol Ther. 2010. PMID: 20668448

6

The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants.

Wangge G, Roes KC, de Boer A, Hoes AW, Knol MJ. Wangge G, et al. CMAJ. 2013 Feb 19;185(3):222-7. doi: 10.1503/cmaj.120142. Epub 2012 Aug 20. CMAJ. 2013. PMID: 22908144 Free PMC article. No abstract available.

7

Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery.

Wangge G, de Boer A, Klungel OH, Hoes AW, Knol MJ. Wangge G, et al. Thromb Res. 2013 Apr;131(4):368-71. doi: 10.1016/j.thromres.2013.01.013. Epub 2013 Mar 7. Thromb Res. 2013. PMID: 23466215 No abstract available.

8

Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs.

Bernabe R, Torres C, Wangge G, Jimenez E, Karbwang J. Bernabe R, et al. Among authors: wangge g. Drug Discov Today. 2022 Mar;27(3):686-689. doi: 10.1016/j.drudis.2021.12.002. Epub 2021 Dec 11. Drug Discov Today. 2022. PMID: 34906688 Free PMC article.

9

Developing alerting thresholds for prospective drug safety monitoring.

Wangge G, Schneeweiss S, Glynn RJ, Gagne JJ. Wangge G, et al. Pharmacoepidemiol Drug Saf. 2016 Jul;25(7):755-62. doi: 10.1002/pds.3905. Epub 2015 Nov 24. Pharmacoepidemiol Drug Saf. 2016. PMID: 26596260

10

Adapting clinical guidelines in low-resources countries: a study on the guideline on the management and prevention of type 2 diabetes mellitus in Indonesia.

Widyahening IS, Wangge G, van der Graaf Y, van der Heijden GJ. Widyahening IS, et al. Among authors: wangge g. J Eval Clin Pract. 2017 Feb;23(1):121-127. doi: 10.1111/jep.12628. Epub 2016 Sep 4. J Eval Clin Pract. 2017. PMID: 27592587 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page